tirzepatide fda ruling Tirzepatide, FDA, and Compounding: Understanding the Current Landscape fda tirzepatide decision court ruling

GLP-1 receptor agonists should be used cautiously in patients with severe gastrointestinal disease or previous pancreatitis

2026 Incretins (GLP-1) and glucose dependent insulinotropic peptide (GIP) are small peptides produced by cells of the small intestine as a response to the ingestion of various nutrients

Mitigation: adequate protein intake (this protects against protein deficiency-related hair loss), zinc supplementation, biotin supplementation, iron monitoring particularly in women (the semaglutide and menstrual cycle guide covers hormonal and nutritional considerations for women)

These changes may persist

PlexusDx supports this gradual approach with personalized guidance aligned with your treatment goals